Difference between revisions of "Prostate cancer"
Jump to navigation
Jump to search
m (PCA3 links) |
m (formatting of headers) |
||
Line 5: | Line 5: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | + | =Metastatic castrate-resistant disease= | |
− | + | ==Cabazitaxel (Jevtana)== | |
− | + | ===Regimen=== | |
*[[Cabazitaxel (Jevtana)]] 25 mg/m2 IV over 1 hour on day 1 | *[[Cabazitaxel (Jevtana)]] 25 mg/m2 IV over 1 hour on day 1 | ||
*[[Prednisone (Sterapred)]] 10 mg PO on days 1-21 | *[[Prednisone (Sterapred)]] 10 mg PO on days 1-21 | ||
Line 16: | Line 16: | ||
*"Antihistamine, corticosteroid (dexamethasone 8 mg or equivalent), and histamine H2-antagonist (except cimetidine)" given at least 30 minutes before cabazitaxel | *"Antihistamine, corticosteroid (dexamethasone 8 mg or equivalent), and histamine H2-antagonist (except cimetidine)" given at least 30 minutes before cabazitaxel | ||
− | + | ===References=== | |
# de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20888992 PubMed] | # de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20888992 PubMed] | ||
− | + | ==Mitoxantrone (Novantrone)== | |
− | + | ===Regimen=== | |
*[[Mitoxantrone (Novantrone)]] 12 mg/m2 IV over 15-30 minutes on day 1 | *[[Mitoxantrone (Novantrone)]] 12 mg/m2 IV over 15-30 minutes on day 1 | ||
*[[Prednisone (Sterapred)]] 10 mg PO on days 1-21 | *[[Prednisone (Sterapred)]] 10 mg PO on days 1-21 | ||
Line 26: | Line 26: | ||
'''21-day cycles x up to 10 cycles''' | '''21-day cycles x up to 10 cycles''' | ||
− | + | ===References=== | |
# de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20888992 PubMed] | # de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. [http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961389-X/fulltext link to original article] '''contains protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/20888992 PubMed] | ||
− | + | =Links= | |
*[http://urology.jhu.edu/prostate/partintables.php Partin tables] to predict pathologic stage based on clinical TNM stage, PSA, and Gleason score | *[http://urology.jhu.edu/prostate/partintables.php Partin tables] to predict pathologic stage based on clinical TNM stage, PSA, and Gleason score | ||
*[http://www.diagnocure.com/en/products-projects/prostate-cancer/pca3-test-healthcare-practitioners.php PCA3 RNA urine test] | *[http://www.diagnocure.com/en/products-projects/prostate-cancer/pca3-test-healthcare-practitioners.php PCA3 RNA urine test] | ||
**[http://www.pca3.org/ PCA3.org] | **[http://www.pca3.org/ PCA3.org] |
Revision as of 04:10, 21 April 2012
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Metastatic castrate-resistant disease
Cabazitaxel (Jevtana)
Regimen
- Cabazitaxel (Jevtana) 25 mg/m2 IV over 1 hour on day 1
- Prednisone (Sterapred) 10 mg PO on days 1-21
21-day cycles x up to 10 cycles
Supportive medications:
- "Antihistamine, corticosteroid (dexamethasone 8 mg or equivalent), and histamine H2-antagonist (except cimetidine)" given at least 30 minutes before cabazitaxel
References
- de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. link to original article contains protocol PubMed
Mitoxantrone (Novantrone)
Regimen
- Mitoxantrone (Novantrone) 12 mg/m2 IV over 15-30 minutes on day 1
- Prednisone (Sterapred) 10 mg PO on days 1-21
21-day cycles x up to 10 cycles
References
- de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2;376(9747):1147-54. link to original article contains protocol PubMed
Links
- Partin tables to predict pathologic stage based on clinical TNM stage, PSA, and Gleason score
- PCA3 RNA urine test